Welcome to our dedicated page for Genelux news (Ticker: GNLX), a resource for investors and traders seeking the latest updates and insights on Genelux stock.
Genelux Corporation develops oncolytic viral immunotherapies for cancer as a late clinical-stage immuno-oncology company. News about GNLX commonly centers on Olvi-Vec (olvimulogene nanivacirepvec), its proprietary modified vaccinia virus, and clinical development in platinum-resistant or refractory ovarian cancer, small cell lung cancer and non-small cell lung cancer.
Company updates also cover quarterly financial results, research and development spending, cash runway disclosures, equity financing activity, conference presentations and management changes tied to clinical development and medical strategy. Genelux has also disclosed an exclusive Greater China license for Olvi-Vec with Newsoara.
Genelux (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, has announced a proposed public offering of its common stock and accompanying warrants. This offering is underwritten, with Guggenheim Securities acting as the sole book-running manager and Newbridge Securities as the co-manager. Genelux plans to grant underwriters a 30-day option to purchase an additional 15% of the shares sold.
The offering is backed by an effective shelf registration statement filed with the SEC, and a preliminary prospectus supplement will be filed. The completion of the offering is subject to market conditions and other customary closing conditions.
Genelux reported its first-quarter 2024 financial results and provided updates on its business activities. The company is progressing with its pivotal Phase 3 registration trial of Olvi-Vec in platinum resistant/refractory ovarian cancer and plans to expand its use into other cancer indications. Genelux is also enrolling patients in clinical trials for non-small cell lung cancer and recurrent small cell lung cancer. The company filed a shelf registration statement to offer up to $300.0 million in common stock, preferred stock, debt securities, and warrants. Financially, Genelux had $19.6 million in cash, cash equivalents, and short-term investments as of March 31, 2024. Research and development expenses increased by $1.2 million year-over-year, while general and administrative expenses increased by $0.3 million in the first quarter of 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.